We examined global gene expression profiles of peripheral blood mononuclear cells (PBMCs) in patients with ulcerative colitis (UC), and tested whether the identified genes with the altered expression might be associated with susceptibility to UC. Methods: PBMCs from 8 UC and 8 normal healthy (NH) volunteers were collected, and total RNAs were subjected to the human 8.0K cDNA chip for the microarray analysis. Real time-PCR (RT-PCR) was performed to verify the results of microarray. One hundred forty UC patients and 300 NH controls were recruited for single nucleotide polymorphism (SNP) analysis. Results: Twenty-five immune function-related genes with over 2-fold expression were identified. Of these genes, two chemokines, namely, CXCL1 and CCL20, were selected because of their potential importance in the evocation of host innate and adaptive immunity. Four SNPs were identified in the promoter and coding regions of CXCL1, while there was no significant difference between all patients with UC and controls in their polymorphisms, except minor association at g.57A G (rs2071425, p=0.02). On the other hand, among three novel and one known SNPs identified in the promoter region of CCL20, g.-1,706 G A (p=0.000000055), g.-1,458 G A (p=0.0048), and g.-962C A (p=0.0006) were found to be significantly associated with the susceptibility of UC. Conclusion: Altered gene expression in mononuclear cells may contribute to IBD pathogenesis. Although the findings need to be confirmed in other populations with larger numbers of patients, the current results demonstrated that polymorphisms in the promoter region of CCL20 are positively associated with the development of UC. (Immune Network 2005;5(4):205-214)
Introduction
The chronic inflammatory bowel diseases (IBDs) ulcerative colitis (UC) and Crohn's disease (CD) remain the most problematic of gastrointestinal disorders. Although the etiologies are unknown, there is evidence linking microbial, immunologic, and genetic factors with pathogenesis of IBD (1) (2) (3) . Genetic factors seem to have a more dominant role in the path-ogenesis of CD than UC, because family rates, concordance rates for monozygotic twins, and concordance rates in offspring for disease type are in general high in CD (4) . For example, positive associations with the CARD15/NOD2 gene on chromosome 16 (IBD1), OCTN1/SLC22A4-OCT/SLC22A5 genes on chromosome 5q (IBD5), and DLG5 on chromosome 10q23 have been established in CD (5) (6) (7) . However, UC also has a high incidence in certain families and shares some susceptibility genes with CD. A linkage between UC and certain regions on chromosomes 3, 7, and 12 has been reported (8) . Recently, suggestive linkage to chromosome 2q also has been reported for the UC phenotype (9) . However, so far, MDR1, a gene of P-glycoprotein, is the only gene identified for 3the susceptibility to the UC pathogenesis (10) .
Ulcerative Colitis is Associated with Novel Polymorphisms in the Promoter Region of MIP-3 /CCL20 Gene
Microarray analysis can complement genetic mapping strategies as a means of identifying susceptibility candidate genes in complex diseases. Microarray has been used to study gene expression in mucosal biopsies from patients with UC, patients with CD, and healthy controls (11) (12) (13) and identified new categories of genes with altered expression, including defensin, Reg, Gro, and calcium-binding S100 genes. Two recent studies of colonic gene expression in patients with UC and controls also detected increased expression of colon cancer-related Wnt signaling and osteopontin genes in UC patients (14, 15) .
Recently, the discovery that CARD15/NOD2, a protein primarily expressed in mononuclear cells, could contribute to organ-specific disease placed mononuclear cells and innate immunity at the center of IBD pathogenesis for the first time (5, 16, 17) . In addition, the Runx 1 gene has been identified as a susceptibility gene for rheumatoid arthritis (18) . Runx 1 is a gene primarily expressed in hematopoietic cells that, when fused to a variety of other genes, plays a role in myeloid malignancies. Polymorphisms in Runx 1-binding sites in the genes encoding SLC22A4, SLC9A3R1, and PDCD1 confer susceptibility to autoimmune diseases, rheumatoid arthritis, psoriasis, and systemic lupus erythematous (18) . These data support the notion that hematopoietic cells may play a central role in chronic, inflammatory, and auto-immune conditions.
Here, we therefore evaluated the utility of patients' blood cells, a readily accessible source of material, for the identification of global gene expression pattern in UC because the NOD2 and Runx 1 findings implicate mononuclear cells in the pathogenesis of IBD and other autoimmune disorders. We compared UC patients to sex-matched healthy controls to identify genes that were specific to the disease and immune function. Further, to test whether the identified genes with the altered expression in PBMCs could be candidate susceptibility genes to UC pathogenesis, we analyzed single nucleotide polymorphisms (SNPs) of those genes selected. Among 222 genes with over 2-fold expression in UC patients, we identified 25 immune function-related genes. Of these genes, two chemokines, namely, CXCL1 and CCL20, were selected because of their potential importance in the evocation of host innate and adaptive immunity. We scanned the chromosomes of 40 healthy volunteers for the identification of SNPs in the CXCL1 and CCL20 genes. Further, we investigated the genotype distributions and allele frequencies of the SNPs in patients with 140 UC patients vs. 300 unrelated non-UC healthy controls.
Materials and Methods
Patients and samples. Human peripheral blood mononu- (19) . The study was approved by the ethics committees of the Medical Faculty of the Wonkwang University, Korea. All participating subjects gave written, informed consent. RNA isolation. Total RNA was prepared from peripheral blood mononuclear cells (PBMCs) using easy-Blue TM (Intron Biotechnology, Korea) following the manufacturer's instructions. Purity and RNA integrity were evaluated by absorbance at 260 nm and 280 nm. High quality RNAs with A260/A280 ratio over 1.9 and intact ribosomal 28S and 18S RNA bands were utilized for the specific purposes described below. The exact amount of RNA required for a given experiment was range from 15 g to 20 g. cDNA microarray analysis. Total RNA was subjected to reverse transcription while being labeled with either Cy3 or Cy5 by means of 3DNA indirect labeling kit, according to the protocol provided by the manufacturer (Genisphere, Inc., Hatfield, PA). For hybridization, Cy3 and Cy5-labeled cDNAs were applied to a human cDNA chip containing approximately 7500 cDNA clones with 90% known sequences and 10% EST (HSVC V1.0, GenomicTree Inc, Korea). Hybridized slide was scanned with ScanArray 3000. Signal quantification and data processing were performed using Imagene 5.1 and GeneSight 3.5 (BioDiscovery, Inc., El Segundo, CA). Each experiment was repeated three times to reduce a high risk of false positive or false negative results. The results from three independent identical experiments were merged and the merged data were used for subsequent comparisons. The average intensity values of Cy3 and Cy5 for each gene were calculated. Significant differences in gene expression between controls and UC patinets were deter-mined using the Student's t-test with a significance threshold of p 0.05. To estimate fold induction, the ratios of Cy5 (treated) to Cy3 (untreated) signal intensities were calculated. The log base 2 of each ratio was determined in order to equalize the magnitude of deflection of up-regulated and down-regulated genes, and gene expression differences were ranked based on absolute values. Real-time quantitative PCR. CCL20 and CXCL1 mRNA levels and GAPDH mRNA levels in PBMCs were quantified using a fluorogenic 5'-nuclease PCR assay (20) with a GeneAmp 5,700 sequence detection system (ABI/Perkin-Elmer). For each standard or sample, duplicated reactions containing 2.5 ml of cDNA were incubated for two minutes at 50 o C, denatured for 10 min at 95 o C, and subjected to 40 cycles of annealing at 55 o C for 20 seconds, increasing to 60 o C for one minute, followed by denaturation at 95 o C for 15 seconds. The gene specific primers used were the same as described above. To detect amplicons generated using the gene specific primers, dual-labeled fluorogenic (Taqman) probes containing FAM (at the 5' end) and TAMRA (at the 3' end) were synthesized (Sigma-Genosys, the Woodlands, Texas, USA). The Taqman probes used included: CCL20, 5'-TGCTAC TCCACCTCTGCGGCGAA-3, CXCL1, 5'-TGGTA GCCGC TGGCCGGCGC-3, and GAPDH, 5'-ACC CAGAAGACTGTGGATGGCCCC-3'. The number of amplicons in each sample reaction was determined by comparison with a standard curve generated using five 10-fold dilutions of plasmids (10 pg to 1 fg) containing CCL20, CXCL1, or GAPDH cDNA. CCL20 and CXCL1 mRNA levels are presented as the number of amplicons per 10 4 GAPDH amplicons. PCR and DNA sequencing. The coding regions of CCL20 and CXCL1 containing the promoter regions were partially amplified by PCR with specific primers using a Perkin-Elmer 9,600 thermal cycler (Perkin-Elmer, Norwalk, CT). PCR was run for 30 cycles of denaturation at 95 o C for 30 seconds, annealing at melting temperature of the each primer pair for 40 seconds, and extension at 72 o C for 1 minute or 3 minutes. Both sense and antisense strands of PCR products were directly sequenced using the same primers used for the PCR amplification. PCR products purified by PCR purification kit (Millipore, Milford, MA) were used as the template DNA for cycle sequencing. Sequence analysis was performed by Big Dye Terminator cycle sequencing using an ABI 3100 Prism Automated DNA sequencer (Applied Biosystems, Foster City, CA) according to the manufacturer's instruction. Genotyping. Genotyping was performed by single-base extension (SBE) method with the ABI Prism SnaPshot Multiplex kit (Applied Biosystems). Eight SBE primers used in this study are listed in Table II . The SBE reaction mixture was prepared according to the manufacturer's instructions. The primer extension reaction was performed at 96 o C for 1 minute, followed by 25 cycles at 96 o C for 10 seconds, 55 o C for 40 seconds, and 60 o C for 30 seconds. To clean up the primer extension reaction, 1.5 unit of CIP (New England BioLabs, Boston, MA) was added to the reaction mixture, and the mixture was incubated at 37 o C for 90 minutes, followed by 15 minutes at 72 o C for purposes of enzyme inactivation. The purified exten-sion products were added to Hi-Di formamide (Applied Biosystems) according to the recommendations of the manufacturer. The mixture was incubated at 95 o C for 5 minutes, followed by 5 minutes on ice, and then electrophoresis was performed with the ABI Prism 3,100 Genetic Analyzer. The results were analyzed by the ABI Prism Gene-Scan and Genotyper software (Applied Biosystems). Statistical analysis. 2 tests were used to estimate the Hardy-Weinberg equilibrium. Logistic regression analyses were used to calculate odds ratios (95% con- 
GCCAGGCTGGGGAAACTGCATTCGGA ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ a Calculated from the translation start site. fidence interval) for SNP sites. Linkage disequilibrium analyses by pairwise comparison of biallelic loci and haplotype and their frequencies were constructed with an EM algorithm or Permutation test with genotyped SNPs. Fisher's exact test or 2 test from 2×3 contingency table was applied to analyze the comparison of the frequency of discrete variables between UC patients and unrelated NH controls. A P value of less than 0.05 was considered to indicate statistical significance.
Results
Genes altered in expression in PBMCs from patients with UC as compared to NH controls. The expression levels of each gene from NH controls (labeled with Cy3 before hybridization) vs. that of UC (Cy5 labeled) are plotted in Fig. 1 . Accordingly, genes whose expression is unchanged lie on the central diagonal while genes whose expression is changed over 2-folds are plotted upper diagonals ( Fig. 1 ). We identified that 611 and 546 genes are over 2-fold expressed in fe-male and male UC patients, respectively. Among these genes, we could extract 222 genes which are over 2-fold expressed in both sexes compared with female or male of NH controls (Fig. 1 ). Finally, we identified 25 genes whose functions are known to be related with immunity and listed in Table III .
We primarily interested in chemokines because these proteins play central roles in the evocation of host innate and adaptive immunity. Moreover, some of these chemokines, including CXCL1 and CCL20, are known to be expressed in mucosal tissues of UC patients and may possibly involve in the pathogenesis of IBD (21, 22) . Most interestingly, the chromosomal location of CCL20 is in 2q33-q37 and this site is well correlated with the recently identified susceptibility loci (2q24-q34 for UC) defined by genome wide meta-analysis (9) .
To validate the accuracy of microarray expression profiling data, we performed real-time quantitative PCR Taqman assays. As shown in Fig. 2 , the mean values of each CCL20 and CXCL1 mRNA levels (Fig. 1 ), 25 genes whose functions are known to be related with immunity are selected. b Data are expressed as fold increase, as compared to the NH controls.
were significantly higher (CCL20, 4.6-fold; CXCL1, 3.4-fold; p 0.05 for both) in the PBMCs of UC patients than in NH controls. This result corroborates that two methods used in the present study reveal overall qualitative agreement. Polymorphisms in the CCL20 gene of UC patients. The human CCL20 gene is encoded an open reading frame of 291 bp, consisting of 4 exons and 5-UTR regions separated by intron. To determine the novel molecular variations in the coding and promoter region of human CCL20 gene, we performed the gene scanning by direct sequencing on genomic DNA samples isolated from 40 unrelated NH controls. We identified a total of 4 SNPs including 3 novel (g.-1,706 G A, g.-1,458 G A, and g.-962 C A) and one known SNPs (g.-786C T (rs6749704)) in the promoter regions. To precisely determine whether these SNPs are associated to susceptibility of UC in Korean population, we analyzed the genotypes and haplotypes for four SNPs (g.-1706 G A, g.-1458 G A, g.-962 C A, and g.-786 C T) by SBE method. All genotype frequencies were in Hardy-Weinberg equilibrium (data not shown).
The p values of each SNP were analyzed in UC patients and NH controls (Table IV) . The genotype and allele frequencies of g.-1706 G A in patients with UC were strikingly different from those in NH controls (p=0.000000055 and p=0.000000003, respec- tively). Most interestingly, compared with NH controls, there was a significant overrepresentation of patients homozygous for the g.-1706G A allele in UC. A total of 17.1% of UC vs. 38.0% of controls were homozygous G, and 38.6% vs. 16.3%, respectively, were homozygous A. The overall OR of developing UC for the presence of 2 A alleles was approximately 5-fold increased (OR, 5.23, 95% CI, 2.91-9.40). The genotype and allele frequencies of g.
-1458G A were also significantly different (p= 0.0048 and p=0.0011; respectively). The genotype frequencies of g.-962C A were higher in patients with UC than those with controls (p=0.0006), while allele frequencies of g.-962C A were not significant (p=0.432; Table IV ). These results are strong evidence of which the CCL20 is associated with the susceptibility to UC.
We next calculated the haplotype frequencies among the g.-1706 G A, g.-1458 G A, and g.-962 C A of CCL20 gene between UC patients and NH controls. As a result, strong allelic associations (haplotypes) among SNPs were detectable in either the UC patients or NH controls (Table V) . Among 8 haplotypes identified in both groups, NH group represented 4 major haplotypes with 93.9% of distribution, while UC group showed 3 major haplotypes with 88.9% of (Table V) . Strikingly, although the estimated haplotype frequencies of two major types (G-A-C and A-A-A) were similar in both groups (UC=63.5%: NH=61.0%), the haplotype frequencies of G-G-C and A-A-C were significantly different between UC and NH (G-G-C: 3.2% and 17.9%, respectively, p=2 ×10 -9
; A-A-C: 25.4% and 15.0%, respectively, p= 0.0002). Taking all the data together, it could be suggested that the promoter region of CCL20 gene is highly associated with the susceptibility to UC in Korean population. Polymorphisms in the CXCL1 gene of UC patients. We identified a total of 4 SNPs, including one novel (g. -38G T) and three known (g.-520T C (rs 3117604), g.57A G (rs2071425), and g.957A G (rs 4074)) SNPs around the CXCL1 locus mapped on 4q12-q13. We next analyzed the genotype frequencies and allele frequencies between the UC patients and NH controls. The SNPs examined in this study revealed no significant differences, except one minor association at g.57A G (p=0.02 and p=0.01, respectively), in their genotype and allele frequencies between UC patients and NH controls (Table VI) . Accordingly, although there was a limitation in the number of the patients used in this study, i.e., the number of the patients used were relatively small; the typing data suggested that the CXCL1 gene could not be a major risk factor conferring the susceptibility to UC at least. We further examined allelic associations among 4 SNPs, but found no significant difference between the patients and controls (data not shown). These results suggest that CXCL1 gene is not associated with the susceptibility to UC in Korean population. Thus, it is conceivable that the CXCL1 gene could contribute to only inflammatory response in the course of the development of UC, but not participate in the pathogenesis of UC as a genetic factor conferring the predisposition to UC.
Discussion
The exact molecular mechanisms that give rise to UC and CD remain poorly understood. It is believed, however, that in genetically susceptible individuals, both disorders result from an inappropriate or excessive immune response to environmental factors, such as elements of the intestinal microflora (23) . Since peripheral blood cells not only form the first line of defense against exogenous putative pathogens, but are also recognized as active participants in inflammatory reactions, increased expression of CCL20 or CXCL1 in the PBMCs suggests that these chemokines may positively associated in the pathogenesis of UC. In fact, at least a dozen polymorphic genes are known to regulate IBD by positive association (2, (24) (25) (26) (27) (28) (29) . However, their associations to UC are not signi-ficant but predisposed only to the some population (7) .
In the current study, we found a striking difference of the genotype and allele frequencies at g.-1706G
A in CCL20 gene of UC patients compared with NH controls (GG vs. AA, p=0.000000055, OR, 5.23; G vs. A, p=0.000000003, OR, 2.4). The genotype and allele frequencies at g.-1458G A and -962C A were also significant in patients with UC than those with controls (see Table IV ). In addition, the estimated haplotype frequencies resulted in significant difference between UC and NH controls (Table V) . So far as we know, the present results demonstrate that CCL20 is the only chemokine gene which shows a strong association with the susceptibility to UC.
The fact that the allele and CCL20 -1706AA genotype frequency is clearly overrepresented in UC patients compared in NH controls makes it unlikely that this association occurred by chance. How or whether CCL20 could be involved in the pathogenesis of UC is presently unknown. However, increased expression of CCL20 in PBMCs ( Fig. 1 and 2) and inflamed colonic tissues (22) of UC patients supports a potential importance of this gene in the pathogenesis of UC. In addition, since CCL20 is thought to link innate and acquired immunity by attracting immature dendritic cells, effector memory T cells and B cells via CCR6 (30) , this gene could be a key regulator of immune function-related diseases, not just for UC but for other immune disorders such as rheumatoid arthritis or asthma. Thus, characterizing the genotype and allele frequencies of these polymorphisms with other autoimmune diseases are one of our on-going projects.
Moreover, a recent genome wide meta-analysis for searching IBD susceptibility loci yielded a strong evidence for linkage to markers on chromosome 2q24-q34 with UC (9). Because region on chromosome 2q is the same region where the CCL20 gene (2q33-q37) is localized, this finding supports our assumption that the polymorphisms in the promoter region of CCL20 may confer a genetic predisposition to UC. Further genetic-association studies are needed to clarify in more detail the contribution of other genes which are located in the same chromosomal loci to susceptibility for UC. Although we did not currently investigate the association of CCL20 with CD because of its lower incidence in Korean population, it will be very interesting whether these polymorphisms in CCL20 are also predisposed in CD.
In the last 10 years, a global effort involving linkage disequilibrium mapping and positional cloning studies of multiply affected families with inflammatory diseases has uncovered a growing number of susceptibility loci on chromosomes 1, 2, 3, 4, 5, 7, 10, 12, 16, 17, 22, and X (8, 9, (31) (32) (33) (34) (35) (36) (37) . However, so far, not many specific gene associations with susceptibility to UC have been identified. Microarray can complement genetic mapping strategies as a means of uncovering candidate susceptibility genes in complex diseases. Parallel use of classical genetic strategies with microarray technique may enhance the chance to find genetic susceptibility genes that are predisposed in immune disorders, including UC and CD.
In summary, the identification of NOD2 as the IBD1 susceptibility gene underscored the significance of mononuclear cells in the pathogenesis of IBD and autoimmunity in general (16) . Using microarray analysis, we have detected differential expression of a wide variety of genes in PBMCs from patients with UC as compared to NH controls. Of those differentially expressed genes, we selected two chemokines, namely CCL20 and CXCL1, because of their potential importance in host immunity. We identified that the polymorphisms g.-1706G A, g.-1458G A, and -962C A in the promoter region of the CCL20 gene are positively associated with UC, thereby suggesting that microarray could be a useful technique to identify genetic susceptibility genes when this technique is combined with classical genetic studies. Further studies are needed to clarify which targets may trigger intestinal inflammation in cases with high expression of CCL20.
